A new center at the University of Cambridge, in collaboration with AstraZeneca and GSK, aims to use AI to make medical discoveries, accelerate the development of precision medicine and develop new treatments

On 10 November the University of Cambridge announced a five-year agreement with AstraZeneca and GSK to fund the Cambridge Centre for AI in Medicine (CCAIM). For the 5-year duration, AstraZeneca and GSK will support five new Ph.D. studentships per year. This program will enable the best and brightest young minds in machine learning and bioscience to partner with leaders in industry and academia, wherever they may be in the world.

CCAIM has been set up as a cutting-edge research group. Its faculty of 10 University of Cambridge researchers – in addition to world-class Ph.D. students, currently being recruited – have united to develop AI and machine learning (ML) technologies aiming to transform clinical trials, personalized medicine, and biomedical discovery. {module INSIDE STORY}

The center’s Director is Professor Mihaela van der Schaar, a world-leading researcher in machine learning (ML), and the Co-Director is researcher-clinician Professor Andres Floto (bios below). The faculty also includes Dr. Sarah Teichmann FMedSci FRS, Head of Cellular Genetics at the Wellcome Sanger Institute and founder and principal leader of the Human Cell Atlas international consortium.

Successfully bridging the gap between the disparate and complex fields of AI and medicine requires building from both sides simultaneously. CCAIM brings together a diverse coalition of leading Cambridge scientists and clinicians, with expertise in machine learning, engineering, mathematics, medicine, computer science, genetics, computational biology, biostatistics, clinical research, healthcare policy and more.

These multi-disciplinary experts from the University of Cambridge will work in close collaboration with scientists and leaders from AstraZeneca and GSK to identify critical challenges facing drug discovery and development that have the potential to be solved through cutting-edge academic research.

The centre’s research output and the implementation of its ML tools could be transformational not only for the pharmaceutical industry – including in clinical trials and drug discovery – but also for the clinical delivery of healthcare to patients. The CCAIM team already has deep research links with the NHS, and four of the centre’s members are NHS doctors.

Professor Mihaela van der Schaar said:
“Machine learning has the potential to truly revolutionize the delivery of healthcare, to the great benefit of patients, clinicians, and the wider medical ecosystem. But to realize this potential requires true and deep cross-disciplinary understanding – a great challenge because we speak different languages. CCAIM is designed to break down the barriers between machine learning and medical science, to create a unique forum in which we can work together to truly understand the challenges, formalize the problems, and develop practical solutions that can be readily implemented in healthcare.”

Professor Andre Floto said:
“We are thrilled that the Cambridge Centre for AI in Medicine is taking off. From tackling the immediate threats of COVID-19 to the long-term transformation of healthcare systems, our network of experts and incoming Ph.D. students will bring next-level AI to bear on the most pressing medical issues of our time.”

Professor Andy Neely OBE, Pro-Vice-Chancellor for Enterprise and Business Relations, University of Cambridge, said:
“The Cambridge Centre for AI in Medicine is a terrific and timely venture that builds on the strong relationships between the University of Cambridge and global leaders in the pharmaceutical industry, AstraZeneca and GSK.
“The depth and diversity of the CCAIM faculty’s expertise mean it is uniquely positioned to deliver and accelerate the breakthroughs in medical science and healthcare that AI has long promised. I anticipate the center’s impact will be nothing less than transformational.”
Jim Weatherall, Vice President, Data Science & AI, R&D, AstraZeneca, said:
“We know the best science doesn’t happen in isolation which is why collaboration is essential to the way we work. This new center combines world-class academia with real-world industrial challenges and will help to develop cutting-edge AI to potentially transform the way we discover and develop medicines.”

Kim Branson, Senior Vice President and Global Head of AI/ML, GSK, said:
“The new Cambridge Centre for AI in Medicine will recruit and train the next generation of practitioners at the intersection of AI, industry, and academia. The work of this institute will be critical to translating AI methods from theory to practice, so that we can keep improving our therapeutic discovery efforts and so that together we can make a tangible impact on patients, from diagnosis to treatment and beyond.”